PDX-Derived Esophageal Cancer Organoid Model

Esophageal cancer (EC) includes esophageal squamous cell carcinoma and esophageal adenocarcinoma, whose therapeutic effect is resisted by biological flaws of existing preclinical models. At Creative Biolabs, we have built a professional team to study new 3D modeling technologies such as PDX-derived EC organoids to serve our new and existing customers.

Shortcomings of Common Models

Some common models of EC show considerable shortcomings. For example, 2D cell line models lack the tumor in vivo environment and prefer to lose cell attributes in the process of passages. Besides, their defects of low heterogeneity and experimental predictability are very obvious. For animal models including ordinary mouse models and patient-derived xenograft (PDX) tumor models, their inability of reflecting the specific human response to tumors or the expensive cost of establishing and maintaining are the most worrying issue.

Advantages of PDX-derived Esophageal Cancer Organoid Models

The organoids from PDX models are called PDX-derived tumor organoid (PDXO) models. The EC PDXOs have been established in recent years as a useful addition to current models. Such models are gradually known for a series of advantages in the EC research field.

• Facilitate preclinical drug validation with relatively short modeling time as compared with animal models.
• Reduce unnecessary waste of resources with a high success rate.
• Show similar structure and physiology to natural organ systems.
• Precisely summarize and reflect the primary characteristics and clonal structure of tumors.
• Enable high-throughput drug screening.
• Serve as the link between 2D cell cultures and animal models to predict clinical effects.

Applications

PDO models have brought us a lot of conveniences owing to the high throughput, low cost, and short duration. They offer an excellent choice to conduct compound screening and predictive biomarker identification for precision medicine, and show a bright outlook for applications in drug discovery. Such organoid models are being combined with several emerging biotechnology, promising greater breakthroughs in the scientific community. The related applications of EC PDXO models are as follows.

Fig.1 Applications of PDX-derived esophageal cancer organoid models. (Creative Biolabs)

Related Services

Since its foundation, Creative Biolabs is concentrated on the biotechnology field and can always keep sensitive antennas to various 3D biology technology. Through constant development, we have built a variety of ex vivo physiological models including 3D organoid models, which are highly customizable and allow our customers to study various biological behaviors of tumors. With rich experience in preclinical drug discovery and development, we stand ready to offer the first-rate PDX-derived esophageal cancer organoid model and related services listed below to promote your preclinical drug research more smoothly. For more detailed information, please feel free to contact us.

Related Sections:

• Patient-Derived Organoid (PDO) Model
• PDX-Derived Organoid (PDXO) Tumor Model